Aug 2, 2022Long-lasting Effect of ANAVEX®3-71 Prevents Cognitive Decline in Animal Model of AD at AAIC 2022
Jul 31, 2022Anavex Announces First Entire Clinical Alzheimer’s Gene Pathway Data of ANAVEX®2-73 at AAIC 2022
Apr 27, 2022Anavex Life Sciences Announces Presentations at the IRSF Rett Syndrome Scientific Meeting
Mar 15, 2022Anavex Life Sciences Announces Presentation of Phase 2 Clinical Biomarker Data from PDD study
Feb 4, 2022Anavex Life Sciences Provides Supplemental Information on ANAVEX®2-73 AVATAR Phase 3 Trial
Feb 1, 2022ANAVEX®2-73 (Blarcamesine) AVATAR Phase 3 Trial met Primary and Secondary Efficacy Endpoints
Aug 26, 2021Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 in FragileX Syndrome
Aug 12, 2021Anavex Life Sciences Provides Business Update and Reports Fiscal 2021 Third Quarter Financial Result
Jul 28, 2021Anavex Life Sciences Announces ANAVEX®2-73 Significantly Prevented Aβ (Abeta)-induced Deficits
Jun 27, 2021Anavex Life Sciences Announces ANAVEX®2-73 Improved both Primary Cognitive and Second MDS-UPDRS
Jun 20, 2021Anavex Life Sciences Announces ANAVEX®2-73 Biomarker Correlated with Efficacy Endpoint in Trial
Jun 13, 2021Anavex Life Sciences Reports the Mechanism of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B)
Jun 7, 2021Anavex Life Sciences Announces Exceeding of Enrollment Target for the Precision Medicine ANAVEX®2-73
Jun 3, 2021Anavex Life Sciences Announces Notice of Allowance for U.S. Patent Application ANAVEX®2-73
Apr 11, 2021Anavex Life Sciences Reports the Results of Review by the Independent Data Safety Monitoring Board
Mar 16, 2021Anavex Life Sciences Reports ANAVEX®2-73 featured as a Disease-Modifying Small Molecule in Trials
